Cambridge tests 39 sweeteners on gut bacteria, most change it

Sweeteners are usually sold as chemically inert, something the body doesn't process the way it processes sugar. A new laboratory study from the University of Cambridge complicates that picture. Researchers in Kiran Patil's lab screened 39 commercially used sweeteners, both artificial and natural, against a panel of gut bacterial species and found that about three-quarters of them changed the growth of at least one species tested. Some slowed or stopped the growth of bacteria that are normally associated with a healthy gut.

Cambridge lab screens 39 sweeteners against gut bacteria

The study, led by Sonja Blasche and Vinita Periwal in Kiran Patil's lab at Cambridge's MRC Toxicology Unit, tested the 39 sweeteners against 25 phylogenetically diverse gut bacterial strains grown in culture. Roughly 75 percent of the sweeteners altered the growth of at least one bacterial species, spanning both synthetic compounds like aspartame, saccharin, acesulfame K and sucralose, and naturally derived ones like stevia and its derivatives. The research, published in the journal Molecular Systems Biology, is among the first to test sweetener effects directly on individual gut microbes rather than inferring them from broader dietary studies.

The team didn't stop at sweeteners alone. They also tested each sweetener in combination with other common compounds, including medications, to see whether pairing them changed the effect. That combination testing turned up more than 100 interactions where the combined effect differed meaningfully from either compound tested alone: 34 combinations strengthened the growth-inhibiting effect on a bacterial species, while 68 weakened it.

Diet soda and antidepressants: who this might affect

The most attention-grabbing result involves isosteviol, a steviol-related compound used in food and beverage manufacturing that is structurally related to duloxetine, a commonly prescribed antidepressant. When isosteviol was combined with duloxetine, the pairing strongly suppressed two bacterial species associated with digestive health: Roseburia intestinalis and Parabacteroides merdae. Both species are linked in prior microbiome research to gut barrier health and metabolic regulation, which is part of why researchers flagged the pairing as notable rather than routine.

That finding matters most for people who regularly consume stevia-based sweeteners while taking duloxetine or similar medications, a combination that isn't rare given how widely both diet products and antidepressants are used. Patil, the study's senior author, put it plainly: sweeteners "don't just pass through the body passively, they can interact with gut microbes, and these effects can be amplified or altered by other substances like medications," according to reporting on the study. The broader implication is that sweeteners should be evaluated as biologically active compounds capable of interacting with other things a person eats, drinks or takes, not simply as inert stand-ins for sugar.

How the screening method made the results credible

The strength of the study is in its scale and its controlled setup. Testing 39 sweeteners against 25 bacterial strains, then re-testing many of those pairs alongside other compounds, produced a systematic map of interactions rather than a single anecdotal effect. Because the experiments were run in bacterial culture, with defined concentrations and controlled conditions, the researchers could isolate which specific compound combinations changed bacterial growth and by how much, something that's difficult to tease apart in a real gut, where diet, other microbes and host physiology all interact at once. Coverage in Medical News Today noted the study screened 25 bacterial strains in total against the sweetener panel.

What this doesn't yet tell us

The obvious limitation is that this is in vitro work: bacteria growing in a dish, not a human gut. A compound suppressing a bacterial species in culture doesn't automatically mean the same suppression happens inside a living digestive tract, where bacterial communities compete, cooperate and buffer each other in ways a single-species culture can't capture. The study also doesn't establish that any of these growth changes translate into a measurable health outcome in the people who consume these sweeteners. Confirming that would require feeding studies or clinical trials in humans, which the researchers have not yet reported. For now, the findings identify plausible interactions worth investigating, not a demonstrated health risk.

What comes next

Patil's group has flagged this screening approach as a template for evaluating other classes of food additives against gut bacteria, and the more than 100 sweetener-compound interactions identified here give researchers a shortlist of specific pairings, including the isosteviol-duloxetine case, to prioritize for follow-up work in more complex microbial communities and eventually in animal or human studies. Until that happens, the practical takeaway is narrower than the headline numbers suggest: this is early evidence that sweeteners can act on gut bacteria directly, and that some common medications may change how strongly they do, not proof of a specific health effect from any single product.

References

1. (2026). Study finds common sweeteners can directly alter gut bacteria – Wiley Analytical Science. https://analyticalscience.wiley.com/content/news-do/study-finds-common-sweeteners-can-directly-alter-gut-bacteria
2. Scientists tested 39 sweeteners and found unexpected gut effects | ScienceDaily. ScienceDaily. https://www.sciencedaily.com/releases/2026/07/260716023552.htm